Form 4: Centessa Pharma Exec Sells Shares Under Trading Plan

Centessa Pharmaceuticals plc officer Mario Alberto Accardi exercised stock options and subsequently sold a portion of his shares under a pre-arranged 10b5-1 trading plan.

Summary

• Mario Alberto Accardi, President of the Orexin Program at Centessa Pharmaceuticals plc, engaged in transactions involving the company's ordinary shares.
• On October 27, 2025, Accardi acquired 5,000 ordinary shares by exercising stock options at a price of $8.01 per share.
• Concurrently, on October 27, 2025, he disposed of 8,000 ordinary shares at a price of $25.00 per share.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by Accardi on February 14, 2025.
• Following these transactions, Accardi's direct beneficial ownership of ordinary shares decreased from 202,394 to 194,394.
• He retains direct beneficial ownership of 30,000 share options, which vest in monthly installments starting March 1, 2024, and expire on February 1, 2034.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there is a net sale of shares by an insider, which can sometimes be perceived negatively, the transaction was pre-scheduled under a 10b5-1 plan, mitigating any immediate negative signal. The officer also realized a significant profit from the option exercise and sale.

Positives

• The officer realized a significant profit by selling shares at $25.00, substantially higher than the option exercise price of $8.01.
• The exercise of options indicates that the stock price was well above the strike price, suggesting value in the company's equity.

Negatives

• The officer's direct beneficial ownership of ordinary shares decreased by a net of 3,000 shares (8,000 sold minus 5,000 acquired).

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may observe a slight reduction in direct insider ownership, though the pre-scheduled nature of the transaction under a 10b5-1 plan typically lessens its perceived impact on management's confidence.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction under a pre-arranged 10b5-1 plan. While the officer sold a net of 3,000 shares, this action is not typically indicative of a significant shift in company fundamentals or management's long-term outlook. The transaction itself does not provide sufficient information to warrant a strong buy or sell recommendation, thus a 'hold' stance is appropriate, pending further financial disclosures or strategic updates.

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, Officer Transaction